OneAscent Financial Services LLC Acquires New Shares in Pfizer Inc. (NYSE:PFE)

OneAscent Financial Services LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, according to its most recent filing with the SEC. The fund acquired 25,552 shares of the biopharmaceutical company’s stock, valued at approximately $739,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Olistico Wealth LLC purchased a new position in Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer during the second quarter worth about $29,000. Gladius Capital Management LP grew its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares in the last quarter. Quarry LP purchased a new position in Pfizer during the second quarter worth about $31,000. Finally, Financial Connections Group Inc. purchased a new position in Pfizer during the second quarter worth about $34,000. 68.36% of the stock is currently owned by institutional investors.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on PFE shares. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Wells Fargo & Company upped their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Wolfe Research assumed coverage on Pfizer in a report on Friday. They issued an “underperform” rating and a $25.00 price objective for the company. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Trading Up 0.3 %

Shares of PFE stock opened at $24.88 on Tuesday. The business has a 50-day moving average of $28.55 and a 200 day moving average of $28.65. The stock has a market capitalization of $140.97 billion, a PE ratio of 33.62, a P/E/G ratio of 0.79 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.17) EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.75%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.